Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Conventional third-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Cyclosporin A
The First People's Hospital of Lianyungang
Acute Leukemia
1 trial -
DPP4
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial -
Dapagliflozin Treatment Group
The First People's Hospital of Lianyungang
Atrial Fibrillation (AF)
1 trial -
Daphne Extract Capsules
The First People's Hospital of Lianyungang
Epithelial Ovarian Cancer
1 trial -
Daratumumab
The First People's Hospital of Lianyungang
Antibody-mediated Rejection
1 trial -
Dasatinib
The First People's Hospital of Lianyungang
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1 trial -
Dentoblis
The First People's Hospital of Lianyungang
Gingivitis; Chronic
2 trials -
Deucravacitinib
The First People's Hospital of Lianyungang
Palmoplantar Pustulosis
1 trial -
Dexamethasone
The First People's Hospital of Lianyungang
Cataract
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Old Age
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Anxiety
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Benign Neoplasm of Vocal Fold - Glottis
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Renal Failure
1 trial -
Dexmedetomidine Injection
The First People's Hospital of Lianyungang
Coronary Disease
1 trial -
Dexmedetomidine ropivacaine
The First People's Hospital of Lianyungang
Pharmacological Action
1 trial -
Dexmedetomidine-Esketamine Combination
The First People's Hospital of Lianyungang
Aged
1 trial -
Dexmedetomidine-esketamine combination
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
Dextrometropine and 0.9% sodium chloride solution
The First People's Hospital of Lianyungang
Cataract
1 trial -
Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
The First People's Hospital of Lianyungang
DLL3-expressing Tumors
1 trial -
Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Disitamab Vedotin combined with Zimberelizumab
The First People's Hospital of Lianyungang
Biliary Carcinoma
1 trial -
Docetaxel
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Docetaxel
The First People's Hospital of Lianyungang
Esophageal Neoplasms
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources